MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
-$79,199K
(-111.48%↓ Y/Y)
Change in fair value of
warrant liability
$12,778K
(562.76%↑ Y/Y)
Norgine Agreement
License
$27,639K
Norgine Agreement RDCN
$926K
Norgine Agreement
RDWHIM
$25K
Interest income
$4,576K
(-20.68%↓ Y/Y)
Loss before
provision for income taxes
-$79,158K
(-113.13%↓ Y/Y)
Provision for income taxes
$41K
(-86.77%↓ Y/Y)
Total other income
(expense), net
$7,725K
(1145.33%↑ Y/Y)
License And Other
Revenue
$28,590K
Product
$6,523K
Interest expense
$8,876K
(1.23%↑ Y/Y)
Other (expense)
income, net
-$753K
(-326.81%↓ Y/Y)
Loss from operations
-$86,883K
(-138.68%↓ Y/Y)
Total revenue
$35,113K
(1273.21%↑ Y/Y)
Total operating
expense
-$121,996K
Research and development
$72,723K
(-10.93%↓ Y/Y)
General and
administrative
$43,516K
(-29.26%↓ Y/Y)
Cost of revenue
$5,757K
(622.33%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
X4 Pharmaceuticals, Inc (XFOR)
X4 Pharmaceuticals, Inc (XFOR)